Improving Insulin Sensitivity by Non-invasive Brain Stimulation in Persons With Insulin Resistance

Sponsor
University Hospital Tuebingen (Other)
Overall Status
Unknown status
CT.gov ID
NCT04052399
Collaborator
German Center for Diabetes Research (Other)
20
1
3
25.9
0.8

Study Details

Study Description

Brief Summary

Efforts in curing and preventing obesity and type 2 diabetes (T2D) have been elusive thus far. One reason for that is the lack of understanding of the role of the brain in the development and treatment of the disease. Insulin action in the brain is appreciated to play a vital role in the pathophysiology of T2D, influencing eating behavior, cognition and peripheral metabolism. Whether brain insulin resistance is a cause or consequence of prediabetes is not yet fully understood. Hence, in this project the investigators want to develop a novel tool to treat and prevent type 2 diabetes and to delineate brain mechanisms of insulin resistance in humans. For this purpose, transcranial direct current stimulation (tDCS) will be implemented, which is a powerful tool to stimulate brain networks. In recent studies, it was shown that the hypothalamus is part of a brain network including higher cognitive regions that is particularly vulnerable to insulin resistance. Furthermore, the central insulin response in this network predicted food craving and hunger. The investigators hypothesize that stimulating the hypothalamus-cognitive network will enhance insulin sensitivity and reduce food intake, food craving and hunger. Furthermore, the project will provide the unique opportunity to investigate novel mechanisms of insulin resistance in participants who have been extensively metabolically characterized.

Condition or Disease Intervention/Treatment Phase
  • Device: anodal transcranial direct current stimulation
  • Device: cathodal transcranial direct current stimulation
  • Device: transcranial direct current stimulation
N/A

Detailed Description

Objectives The overarching aim of the study is to stimulate the hypothalamus-cognitive brain network to improve insulin sensitivity and eating behavior.

Specific Objectives- Feasibility study:
  1. Implement resting-state functional magnetic resonance imaging to identify individual medial and lateral hypothalamic cognitive functional networks.

  2. Evaluate and test different non-invasive brain stimulation paradigms by tDCS to stimulate lateral and medial hypothalamus cognitive network on eating behavior and metabolism.

20 participants with overweight and obesity will receive five different tDCS stimulation protocols on five separate days (separated by one week) in a single-blind cluster-randomized order to reduce sequence effects. Optimal stimulation sites are assessed of the lateral and medial hypothalamus-cognitive network based on a modelling approach. Since this is the first study to stimulate the hypothalamus-cognitive network, excitatory as well as inhibitory stimulation is used. To reduce the number of conditions, participant are randomized based on the three main conditions: sham stimulation, anodal and cathodal stimulation. Medial hypothalamus-cognitive network versus lateral hypothalamus-cognitive network stimulation are pseudo-randomised.

Participants will come in the morning, after an overnight fast, to receive a 20 min non-invasive brain stimulation, using tDCS. During the stimulation, participants will perform a stop-signal task on an tablet.

Subsequently, participants will receive a breakfast buffet. The caloric intake from fat, carbohydrates and protein will be documented. Subjective feeling of hunger and food craving will be assessed using a visual analogue scale before stimulation, directly after stimulation and after breakfast. Food pictures will be rated on a laptop for taste and healthiness.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Basic Science
Official Title:
Improving Insulin Sensitivity by Non-invasive Brain Stimulation- Feasibility Study
Actual Study Start Date :
Nov 4, 2019
Anticipated Primary Completion Date :
Dec 31, 2020
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Anodal tDCS

Anodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network (2 conditions)

Device: anodal transcranial direct current stimulation
Anodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.
Other Names:
  • anodal tDCS
  • Active Comparator: Cathodal tDCS

    Cathodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network (2 conditions)

    Device: cathodal transcranial direct current stimulation
    Cathodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.
    Other Names:
  • cathodal tDCS
  • Placebo Comparator: Sham stimulation

    Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds in order to simulate the active condition without any further continuous administration of current)

    Device: transcranial direct current stimulation
    Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds)
    Other Names:
  • tDCS
  • Outcome Measures

    Primary Outcome Measures

    1. Caloric intake (kcal) [1 hour after tDCS]

      The investigators will assess free-choice, ad libitum food intake from a standardized breakfast buffet. The caloric intake from fat, carbohydrates and protein will be documented.

    2. Change in subjective feeling of hunger and food craving [5 minutes before tDCS, 10 min after tDCS and 10 min after breakfast]

      On a visual analogue scale, subjective feeling of hunger and food craving will be assessed using a questionnaire.

    Secondary Outcome Measures

    1. Response inhibition [20 minutes during tDCS]

      To measure the performance during the stop-signal task (i.e. response inhibition) direction errors, proportion of successful stops, reaction time on Go trials, and stop signal reaction time (SSRT) will be measured.

    2. Tastiness and healthiness rating of food stimuli [10 minutes task after breakfast]

      Using a computer based task, participants rate food pictures of low caloric and high caloric foods and snacks on a 5-point scale based on subjective tastiness and healthiness (1=not at all tasty/very unhealthy, 2=not tasty/unhealthy, 5 very tasty/healthy).

    3. Food choice [10 minutes task after rating of food stimuli]

      Using a computer based task, participants have to choose food items they preferred to eat compared to a reference food on a 5-point choice scale. The reference (or "neutral") food item is individually determined based the health and taste rating.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Body mass index (BMI) between 25.5 and 35 kg/m2

    • Age between 20 to 60 years of age

    • Criteria for prediabetes:

    Fasting plasma glucose (PG) 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (impaired fasting glucose) OR 2-h PG during 75-g oral glucose tolerance test 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L) (impaired glucose tolerance) OR HbA1c 5.7-6.4% (39-47 mmol/mol)

    Exclusion Criteria:
    • Insufficient knowledge of the German language

    • Persons who cannot legally give consent

    • Pregnancy or lactation

    • History of severe mental or somatic disorders including neurological diseases (incl. epileptic seizures)

    • Taking psychotropic drugs

    • Previous bariatric surgery

    • Acute infection within the last 4 weeks

    • Hemoglobin values less than 12g/dl for women, less than 14 g/dl for men

    • Current participation in a lifestyle intervention study or a pharmaceutical study

    • Contradictions to a MRI measurement (e.g. metal implants)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Clinic Tübingen Tübingen Germany

    Sponsors and Collaborators

    • University Hospital Tuebingen
    • German Center for Diabetes Research

    Investigators

    • Principal Investigator: Stephanie Kullmann, PhD, University Hospital Tübingen

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital Tuebingen
    ClinicalTrials.gov Identifier:
    NCT04052399
    Other Study ID Numbers:
    • 243/2019BO1
    First Posted:
    Aug 9, 2019
    Last Update Posted:
    May 14, 2020
    Last Verified:
    Aug 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 14, 2020